Best Vector Design Now. Less Risks Later.

Early-stage vector genome optimization is essential to avoiding costly manufacturing delays, low yields, and safety risks downstream in AAV gene therapy development. The Plasmid Optimization (PO) service from Viralgen and TAAV refines vector design early in development to enhance productivity, potency, and safety while reducing immunogenicity. By focusing on two critical dynamics—identifying the optimal Gene of Interest (GOI) and capsid candidate, and analyzing manufacturing platform fit—this service ensures efficient vector genome packaging and high-yield productivity. The workflow transitions seamlessly from construct analysis and theoretical sequence generation to 2L scale runs and final candidate selection, positioning programs for scalable clinical manufacturing from Phase I through Phase II.

Download the full brochure to discover how early vector optimization streamlines your AAV manufacturing pipeline.